Faculty Opinions recommendation of Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Author(s):  
John Nemunaitis ◽  
Luisa Manning
2019 ◽  
Vol 10 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Yuki Katayama ◽  
Tadaaki Yamada ◽  
Keiko Tanimura ◽  
Akihiro Yoshimura ◽  
Takayuki Takeda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document